DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award

The DoW Duchenne Muscular Dystrophy Clinical/Translational Research Award supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. The award has two funding levels: Funding Level 1 for smaller, less complex preclinical and/or clinical research, and Funding Level 2 for larger, more complex preclinical and/or clinical research. The award also offers a Partnering PI Option to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. Preliminary data are required for all applications, and pilot clinical trials and clinical trial readiness studies are allowed. • The award is open to extramural and intramural U.S. Department of War (DOW) organizations, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities. • The award supports research that addresses at least one of the FY26 CTRA Focus Areas, including preclinical translational research and clinical research. • The maximum period of performance is 3 years for Funding Level 1 and 4 years for Funding Level 2. • The award requires a two-step application process, with a pre-application submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a full application submitted through eBRAP or Grants.gov.